Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC9V and High-dose Quadrivalent Influenza Vaccine in Adults ≥65 Years
2023-504168-40-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in invasive extraintestinal pathogenic Escherichia coli disease (IED) and influenza comparing ExPEC9V + Efluelda co-administration, ExPEC9V alone and Efluelda alone (3 arms). Started Sep 2023; status: completed.
02
Drugs
ExPEC9Vinfluenza vaccine (quadrivalent, high-dose)
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)influenza
Beyond the preview
Go deeper on 2023-504168-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504168-40-00.